AstraZeneca CEO says Summit's cancer drug will drive next-gen combination treatments
Pascal Soriot told CNBC that ivonescimab could combine with antibody-drug conjugates to treat tumors that existing immunotherapies handle less well
We haven't written up this one. Quartz has the full story — the link below goes straight to it.